Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Says Best is yet to Come in 2018
DehydraTECH™ is the company’s newly U.S.-patented disruptive drug delivery platform; LXRP CEO Chris Bunka says company is working on more applications for its technology in the treatment of Alzheimer’s disease, Parkinson’s disease, opioid addiction and more LXRP has a portfolio of patents issued in both the U.S. and Australia, plus 19 patent applications filed in … Continue reading “Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) Says Best is yet to Come in 2018”